Abstract
Previously, many studies have reported changes in the gut microbiota of patients with colorectal cancer (CRC). While CRC is a well-described disease, the relationship between its development and features of the intestinal microbiome is still being understood. Evidence linking Fusobacterium nucleatum enrichment in colorectal tumor tissue has prompted the elucidation of various molecular mechanisms and tumor-promoting attributes. In this review we highlight various aspects of our understanding of the relationship between the development of CRC and the alteration of intestinal microbiome, focusing specifically on the role of F. nucleatum. As the amount of F. nucleatum DNA in CRC tissue is associated with shorter survival, it may potentially serve as a prognostic biomarker, and most importantly may open the door for a role in CRC treatment.
| Original language | English |
|---|---|
| Pages (from-to) | 819-827 |
| Number of pages | 9 |
| Journal | Journal of Investigative Medicine |
| Volume | 72 |
| Issue number | 8 |
| DOIs | |
| State | Published - Dec 2024 |
Bibliographical note
Publisher Copyright:© 2024 American Federation for Medical Research.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Sangeeta Tiwari acknowledges grant awards from National Institute of Health NIGMS (SC1GM140968) to support this work.
ASJC Scopus Subject Areas
- General Biochemistry,Genetics and Molecular Biology
Keywords
- Colorectal cancer
- Fusobacterium nucleatum
- gut microbiota
- gut-oral axis
Disciplines
- Biochemistry, Biophysics, and Structural Biology
Fingerprint
Dive into the research topics of 'The role of Fusobacterium nucleatum in the pathogenesis of colon cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS